We are developing a "tumor-targeted minimally invasive therapy" that improves the quality of life of cancer patients who cannot be treated by standard therapy. It is our mission to provide this new therapy as quickly as possible and to contribute to medical treatment with medical technology from Tokyo Tech.
"Tumor-targeted minimally invasive therapy" is a method in which an independently-developed tumor-insulating nanodevice (MD2) is locally administered to a tumor and specifically surrounds the tumor. It is a therapy that blocks oxygen and nutritional supply, thus having an antitumor effect. MD2 used in this therapy has biodegradability and will eventually be degraded in the body.
This therapy is being developed through collaborative research between the Company and Kondoh Laboratory at the Tokyo Institute of Technology Life Sciences Institute.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Nagatsuta-Cho 4259-3, Midori-Ku, E207,japan
- Industry
- Medical Device
- Website
- http://www.medigear.co.jp/
- Keywords
- Nanotechnology, Cancer, Medical Devices, Polymers.
- HQ
- Yokohama, Kanagawa
- Competitors
- MediGear.
Medigear International Corporation Questions
Medigear International Corporation's website is http://www.medigear.co.jp/
Medigear International Corporation's LinkedIn profile is https://jp.linkedin.com/company/medigear-international
Medigear International Corporation has
1 employees.
View email and phone details for 1
employees at Medigear International Corporation.
Medigear International Corporation's industry is
Medical Device
Medigear International Corporation's top competitors are
Medigear.
Medigear International Corporation's categories are Medical Device
Medigear International Corporation's founding year is 2013
